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Triaging multiple myeloma patients for stem cell transplantation
relies heavily on the identiﬁcation of high-risk prognostic factors.
Although a variety of molecular cytogenetic methods are widely
utilized, it is not clear which, if any, has a greater value than others.
In addition, identiﬁcation of the best test(s) would assist in con-
serving valuable resources, especially at smaller centers. We con-
ducted a comparative study on the bone marrow aspirates of 74
consecutive patients with Salmon-Durie Stage I, II, or III disease.
The majority (59/74) of patients were clinically in advanced stage
and planned to undergo therapy. On each patient, image analysis of
morphologically selected interphase plasmacytes was utilized to
ascertain the DNA ploidy level and karyotype analysis was at-
tempted on metaphases obtained following cell culture. Fluores-
cence in situ hybridization (FISH) for RB1 and TP53 was per-
formed in all cases with 	30% bone marrow plasmacytes. Neither
the detection of hypodiploidy or hyperdiploidy by image analysis
or the deletion of TP53 by FISH correlated with survival (P .871
and P  .792, respectively). Deletion of the RB1 locus was ob-
served in 27% of patients tested and tended to signiﬁcance (P 
.270). A karyotype was achieved in 43% of patients. An abnormal
karyotype was observed only in Stage III patients and was signiﬁ-
cantly linked to poor survival by Kaplan-Meier analysis (P  .002).
Evaluating a small cohort with a short observation period and using
the endpoint of death, highlights those tests most linked to ad-
vanced stage disease and identiﬁes those patients most likely to
beneﬁt from stem cell transplantation. A cost-effective algorithm is
suggested in which cytogenetic analysis is performed only on Stage
III patients and FISH for a 13q14 locus alone is performed in those
with 	30% bone marrow plasmacytes.
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OUTCOMES OF SALVAGE CHEMOTHERAPY AND AUTOLOGOUS TRANS-
PLANTATION FOR LARGE CELL TRANSFORMATION OF FOLLICULAR
LYMPHOMA—A COMPARISON OF OUTCOMES WITH RELAPSED/RE-
FRACTORY DIFFUSE LARGE B CELL LYMPHOMA
Kuruvilla, J.1, Chen, C.1, Pintilie, M.2, Nagy, T.1, Keating, A.1,
Crump, M.1 1. University of Toronto Autologous Blood and Marrow
Transplant Program, Princess Margaret Hospital, Toronto, ON, Can-
ada; 2. Clinical Study Coordination, Princess Margaret Hospital, To-
ronto, ON, Canada.
Introduction: Recent data demonstrate that large cell transfor-
mation (TR) of follicular lymphoma (TRFL) has a different gene
expression proﬁle than diffuse large cell lymphoma (DL). Out-
comes of salvage chemotherapy and autologous stem cell trans-
plantation (ASCT) for TRFL are unclear. We compared the over-
all response rate (ORR) to salvage chemotherapy, progression-free
(PFS) and overall survival (OS) of TRFL patients (pts) to pts with
relapsed or refractory (RR) DL. Methods: We reviewed cases
between January 1995 and December 2004 and identiﬁed 56 pts
with biopsy proven DL that had arisen from Follicular Grade 1 or
2 lymphoma treated with chemotherapy with the intent to proceed
to ASCT. One hundred forty-three consecutive pts with RR-DL
who received salvage chemotherapy between January 1, 1999 and
December 31, 2004 served as a control. Pts received anthracycline
or platinum-based salvage therapy to assess chemotherapy sensi-
tivity; responders proceeded to PBSC mobilization and ASCT.
The intensive therapy regimen consisted of high-dose etoposide 60
mg/kg day 4 and melphalan 180 mg/m2 day 3 (with or without
1200 cGy TBI in 6 fractions) with PBSC infusion day 0. Results:
The median age at the initiation of salvage chemotherapy was 54
years (range 31–65) in the TRFL pts versus 53 (21–66) in the
RR-DLBCL pts (P  .31, Wilcoxon). The median time from
diagnosis of FL to diagnosis of TRFL was 4 years (range 0.6–23).
Advanced stage disease at TR was found in 78% of TRFL pts
versus 52% of RR-DLBCL pts (P  .0007 -square). The median
number of treatments for TRFL pts was 2 (range 0–8) while the
median number of prior treatments for RR-DLBCL was 1 (range
1–3). The ORR to ﬁrst line salvage chemotherapy was 50% in
TRFL pts versus 48% in RR-DLBCL pts (P  .79 -square). 50%
of TRFL and 45% of RR-DLBCL pts were able to proceed to
ASCT after all salvage chemotherapy and PBSC mobilization (P
.53, -square). For chemosensitive pts who underwent ASCT, the
2 year OS was similar (36% TRFL, 53% RR-DLBCL, P  .15)
while the 2 year PFS was inferior for TRFL (20% TRFL, 36%
RR-DLBCL, P  .04), with a similar median follow-up in both
groups (TRFL: 2 years, RR-DL 1.8 years). Conclusions: Pts with
TRFL were more likely to have advanced stage disease and were
more pre-treated prior to salvage therapy. The ORR to salvage
chemotherapy was similar but TRFL pts had an inferior PFS
(though not OS) post-ASCT. Studies should focus on developing
prognostic models to risk stratify TRFL, and novel therapies
should be considered.
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PROGNOSTIC FACTORS FOR SURVIVAL OF PATIENTS WITH NON-
HODGKIN’S LYMPHOMA (NHL) AFTER AUTOLOGOUS PERIPHERAL
STEM CELL TRANSPLANTATION (APSCT)—SINGLE CENTER EXPERI-
ENCE
Faber, E.1, Vondrakova, J.1, Zapletalova, J.2, Skoumalova, I.1,
Maresova, I.1, Raida, L.1, Papajik, T.1, Indrak, K.1 1. Department of
Hemato-Oncology, University Hospital, Olomouc, Czech Republic; 2.
Institute for Biophysics and Statistics, University Hospital, Olomouc,
Czech Republic.
Several prognostic factors had been previously reported to be
associated with overall and progression-free survival of patients
with NHL after APSCT. We present a retrospective single center
analysis with special attention to the markers that reﬂect the ac-
tivity of disease at the time of transplantation. 122 patients with
NHL indicated for APSCT for high-risk features at diagnosis
partial response to ﬁrst line treatment and/or relapse were included
in the study. There were 66 women and 56 men at median age 45.5
years (range 19–66). Forty-seven patients were with diagnosis of
diffuse-large cell lymphoma, 34 with follicular lymphoma, 15 with
mantle cell lymphoma, and 26 patients had other lymphoma sub-
types. Patients were transplanted in years 1997–2004. In all cases,
BEAM was used for conditioning. Median follow-up of patients
was 27 months (range 3.0–93.9). Fifty (41%) patients relapsed and
35 (28.7%) died. Age, stage of disease, IPI, bone marrow and
extra-nodal involvement, presence of B symptoms and bulky dis-
ease at diagnosis, activity of disease and Karnofski index at the time
of transplantation, response to therapy and levels of serologic
markers (LDH, -2-microglobulin and thymidine kinase) at the
diagnosis and at the time of transplantation were included in
univariate and multivariate analysis. For relapse-free survival level
of LDH at transplantation was identiﬁed as signiﬁcant factor both
in univariate analysis and Cox regression model (RR  3.63; 95%
CI 1.02–12.88, P .046). On the other hand, levels of LDH and
thymidine kinase at diagnosis and levels of LDH, thymidine kinase
and -2-microglobulin together with Karnofski score at transplan-
tation and age were found predictive for overall survival in univar-
iate analysis. Multivariate Cox regression analysis identiﬁed levels
of -2-microglobulin at transplantation (RR  2.59; 95% CI 
1.06–6.37, P  .038) and LDH at transplantation (RR  1.08;
95% CI  1.02–1.15, P  .007) as independent prognostic factors.
We conclude that clinical assessment of disease activity at trans-
plantation was not sufﬁcient for estimation of prognosis in our
patients. Levels of serologic markers as LDH and -2-microglobu-
lin at transplantation were found more useful and signiﬁcantly
correlated with overall survival of our patients with NHL after
APSCT. Supported by grant MSM 6198959205.
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TOTAL MARROW IRRADIATION AND PERIPHERAL BLOOD PROGENI-
TOR CELL RESCUE FOLLOWING HIGH-DOSE MELPHALAN AND PERIPH-
ERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH MULTI-
PLE MYELOMA
Somlo, G.1, Forman, S.1, Popplewell, L.1, Spielberger, R.2, Sahebi, F.2,
Parker, P.1, Schultheiss, T.1, Liu, A.1, Krishnan, A.1, Wong, J.1 1. City
of Hope National Medical Center, Duarte, CA; 2. Kaiser Permanente,
Los Angeles, CA.
Tandem high-dose therapy (THDT) followed by peripheral
blood progenitor cell reinfusion (PBPC) is associated with a pro-
jected 20% progression-free survival at 7 years after treatment for
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patients with multiple myeloma (MM). Combining standard frac-
tionated total body irradiation (TBI) with high-dose melphalan
precludes optimal dosing of melphalan, and results in equivalent
efﬁcacy but more toxicity in comparison to high-dose melphalan
(mel) alone. Helical tomotherapy is a novel tool for delivering CT
image guided intensity modulated radiation therapy and may allow
for greater doses of total marrow irradiation (TMI) and less col-
lateral damage to other organs. We set out to test the feasibility of
THDT inclusive of TMI. Eligible patients (70 years old, with
stages I-III MM, in response or with stable disease, with a creati-
nine clearance of 50 mL/min) underwent mobilization with cy-
clophosphamide 1.5 gm/m2 and G-CSF 10 microgram/kg and
procurement of  4  106 CD34 cells/kg. THDCT consisted
of a set dose of mel 200 mg/m2 followed by PBPC. At a
minimum of 6 weeks later, TMI 200 cGy daily  5 days, (to be
escalated up to 200 cGy twice daily in a standard phase one
cohort by cohort fashion) an PBPC is administered. Upon
recovery, thalidomide 50–200 mg daily and dexamethasone 40
mg/day  4 days every 28 days is to be prescribed. At dose level
1 (TMI: 200 cGy daily  5 days ) two patients (a 53 year old
female with stage I MM in complete response and a 48 year old
male with stage III MM in partial response prior to THDT)
have completed THDT and are currently receiving mainte-
nance. Neutrophyl and platelet recovery following TMI was
observed by days 9 and 11, and platelet independence (deﬁned as
the day after the last platelet transfusion) was observed by day
10. Grade 1 emesis and grade 2 nausea, but no evidence of oral
mucositis, enteritis, or skin erythema were noted. The estimated
reduction in organ exposure to radiation with TBI versus TMI
ranged from 6.5–6.9-fold (lens) to 2.5–2.6-fold (bowel), and
1.4–1.7-fold (lungs) in the ﬁrst two patients treated. TMI is
feasible for patients undergoing THDT for MM. Accrual is
ongoing and results in patients treated at higher doses of TMI
will be presented.
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COMPARISON OF CD34 COLLECTIONS IN PATIENTS WITH MUL-
TIPLE MYELOMA USING ETOPOSIDE/CYCLOPHOSPHAMIDEGCSF,
CYCLOPHOSPHAMIDEGCSF, AND GCSF ALONE MOBILIZATION
REGIMENS
Scott, L.M.1, Brougher, L.I.1, Anderson-Reitz, L.A.1, Ensley, L.1,
Saracino, G.1, Agura, E.D.1, Berryman, R.B.1, Fay, J.W.1,
Pineiro, L.1, Vance, E.A.1 1Baylor Sammons Cancer Center, Baylor
University Medical Center, Dallas, TX.
Introduction: Low risk, curative therapy for patients with
multiple myeloma remains elusive. Autologous stem cell trans-
plant remains the standard of care for newly diagnosed multiple
myeloma. Mobilization of adequate CD34 cells can be a dif-
ﬁcult task, especially in patients who have been heavily pre-
treated. We have compared the three mobilization regimens
utilized at our facility and the subsequent CD34 collections.
Background: Standard chemotherapy is effective in maintain-
ing control of multiple myeloma, however none has proven
curative. Several trials have indicated that tandem or double
autologous transplants may provide a signiﬁcant beneﬁt for
overall survival and event free survival. When double trans-
plants are planned, especially for patients who are heavily pre-
treated, collection of adequate CD34 cells can prove to be
challenging. Methods: 217 patients with multiple myeloma
whose treatment plan included either a single or double autol-
ogous transplant were evaluated retrospectively. Data have been
collected from January 1999 to March 2005. Mobilization reg-
imens utilized were etoposide/cyclophosphamideGCSF,
60 patients; cyclophosphamideGCSF, 34 patients; and
GCSF alone, 123 patients. Peripheral blood stem cells were
collected following standard institutional procedures utilizing
the Cobe Spectra apheresis machine. Standard CD34 cell dose
target for a single transplant was 	2.0  106/kg. Results:
Average and median CD34 cell dose collected for patients
receiving GCSF alone was 24.05  106/kg and 6.3  106/kg;
cyclophosphamideGCSF 13.28  106/kg and 9.75  106/kg;
etoposide/cyclophosphamideGCSF 39.98  106/kg and
30.4  106/kg. The average number of collections required
for each regimen was 2.11 days for GCSF, 1.76 days for
cyclophosphamideGCSF, and 1.4 days for etoposide/cyclophosph-
amideGCSF.Conclusions: Etoposide/cyclophosphamideGCSF
mobilization regimen is highly effective in mobilizing large numbers
of CD34 cells in multiple myeloma patients making double or
tandem transplants a viable treatment option.
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A PILOT STUDY OF CYCLOPHOSPHAMIDE, CARBOPLATIN, ETOPOSIDE
(CCE), AND G-CSF WITH OR WITHOUT RITUXIMAB FOR CYTOREDUC-
TION AND PERIPHERAL BLOOD STEM CELL MOBILIZATION IN PA-
TIENTS WITH RELAPSED OR REFRACTORY LYMPHOMAS
Stevenson, D.E.1, Haroff, A.L.1, Ririe, D.W.1, Splichal, J.E.1,
Ornstein, D.L.2, Heller, B.J.3 1. Wilford Hall Medical Center, Lack-
land AFB, TX; 2. University of Vermont/Fletcher Allen Health Care,
Burlington, VT; 3. Malcolm Grow Medical Center, Andrews AFB, MD.
Background: Salvage chemotherapy is used for cytoreduction
and PBSC mobilization in patients with relapsed and refractory
lymphomas. Hospitalization is generally required for administra-
tion of the most commonly used regimens. We conducted a pilot
study to determine the feasibility of delivering CCE with or with-
out rituximab for cytoreduction and chemomobilization entirely in
the outpatient setting to patients with refractory or recurrent
non-Hodgkin’s or Hodgkin’s lymphoma who were candidates for
high dose therapy with autologous stem cell support. Methods: 2
cycles of CCE were administered at 21 day intervals. The regimen
consisted of cyclophosphamide 1 gram/m2 on day 1, carboplatin at
an AUC of 5 on day 2, and etoposide 100 mg/m2 on days 1, 2, and
3. G-CSF, 5 mcg/kg/day was administered on days 512 with
cycle 1 and the dose was increased to 10 mcg/kg/day for PBSC
mobilization with cycle 2. After the ﬁrst 8 patients, the protocol
was amended to allow the use of rituximab at a dose of 375
mg/m2on days 1, 8, and 15 of each cycle for those patients with
CD20 lymphomas. Results: 18 patients have been enrolled and
have completed CCE. The diagnoses include B-cell non-
Hodgkin’s lymphoma (B-NHL; n  8 large cell, n  2 follicular),
Hodgkin’s lymphoma (n  3), peripheral T-cell lymphoma (n 
2), anaplastic large cell lymphoma (n  1), composite B-NHL/
Hodgkin’s lymphoma (n  1), and T-cell rich, B-cell lymphoma
(n  1). The median age was 46 years (range 19–69). One patient
received one cycle of CCE, while 2 patients received more than 2
cycles. The overall response rate for the regimen is 63% (3 CR, 7
PR, 5 SD, 1 PD, 2 not evaluable). PBSC were collected successfully
from 16/18 patients. The median number of PBSC collected was
7.5  106 CD34 cells/kg (range 2.1–16.8  106), and the median
number of apheresis sessions was 2 (range 1–9). There were 4
hospitalizations for neutropenic fever in 38 cycles. Non-hemato-
logic toxicity was minimal, and no deaths occurred on study. All
patients from whom sufﬁcient PBSC were collected underwent
high dose therapy with autologous PBSC rescue, and hematologic
recovery occurred in 100%. Conclusions: The interim results of
this pilot study suggest that CCE is a safe and effective outpatient
regimen for cytoreduction and PBSC mobilization for relapsed or
refractory non-Hodgkin’s and Hodgkin’s lymphoma. This regi-
men warrants further study, and a total of 30 patients will be
enrolled on this continuing study.
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SALVAGE AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA
Qazilbash, M.H.1, Saliba, R.1, Mendoza, F.1, Roden, L.1, Hosing, C.1,
Couriel, D.1, Kebriaei, P.1, Popat, U., DeLima, M.1, Champlin, R.E.1,
Giralt, S.A.1 1University of Texas-M. D. Anderson Cancer Center,
Houston, TX.
Introduction: Most patients undergoing high-dose therapy and
autologous transplant for multiple myeloma eventually relapse.
The optimal treatment for these patients is still evolving. There
have been few reports of autologous transplants in the salvage
setting. We analyzed the outcome of salvage autologous transplant
in 22 patients with disease progression after the ﬁrst autograft.
Methods: These patients in general were not eligible for an allo-
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